StockData
Agios Pharmaceuticals, Inc. logo

Agios Pharmaceuticals, Inc. (AGIO) company profile

AGIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/308% above fair value
$29.89−0.26 (-0.86%)

Close on Nov 17, 2026Market cap $1.78BP/E –Yield –

About Agios Pharmaceuticals

Pharmaceutical Preparations, SIC 2834

Agios is a commercial-stage biopharmaceutical company focused on discovering and developing therapies for rare hematologic conditions and genetic metabolic disorders. The company's lead commercial product is mitapivat, an oral small-molecule pyruvate kinase activator marketed under the brand names Pyrukynd and Aqvesme for indications including pyruvate kinase deficiency and alpha- or beta-thalassemia. In addition to commercializing mitapivat, Agios advances a clinical development pipeline featuring investigational candidates such as tebapivat for lower-risk myelodysplastic syndromes and sickle cell disease, AG-181 for phenylketonuria, and AG-236 for polycythemia vera. The company serves adult and pediatric patient populations diagnosed with rare hematological and metabolic diseases.

The company maintains commercial infrastructure to distribute its therapies directly in the United States and utilizes third-party distribution partners to provide access across the European Economic Area, Switzerland, the United Kingdom, and the Gulf Cooperation Council region. The excerpt does not provide information regarding the company's specific headquarters location.

Summary of the business section of Agios Pharmaceuticals's latest annual report, written by StockData.

Company profile

Company

Legal name
Agios Pharmaceuticals, Inc.
Founded
2008
Headquarters
Cambridge, MA
Address
88 Sidney Street 02139
Phone
(617) 649-8600
Employees
539, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
PricewaterhouseCoopers LLP, Boston, Massachusetts

Stock & identifiers

Ticker
AGIO
Exchange
Nasdaq
IPO date
Jul 24, 2013
Shares outstanding
60M, Jul 24, 2026
Public float
$1.91B, Jun 30, 2025
Filer category
Large accelerated filer
SEC CIK
1439222
CUSIP
00847X104
ISIN
US00847X1046
FIGI
BBG000QY4ZD0
Share class FIGI
BBG001T8R687
LEI
529900ONJHY8EOGYT555
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Brian GoffChief Executive Officer, Director191,104
Sarah GheuensChief Medical Officer54,645
Tsveta MilanovaChief Commercial Officer46,829
Krishnan ViswanadhanChief Strategy and Operations10,282
James William BurnsChief Legal Officer49,306
Cecilia JonesChief Financial Officer54,998
Theodore James Washburn Jr.Principal Accounting Officer868
Jay T. BackstromDirector1,447
Rahul D. BallalDirector15,230
Cynthia SmithDirector15,230
David ScaddenDirector20,419
Maykin HoDirector19,848
Jacqualyn A. FouseDirector154,156
Jeffrey D. CapelloDirector10,865
Adams Catherine OwenDirector10,865
Kaye I. Foster-CheekDirector12,484

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025
Brian Goff
$5.37M$5.98M$2.44M$63$120
FY2025
Jacqualyn AFouse Ph D
$0$0$2.44M$63$120
FY2024
Brian Goff
$6.78M$12.97M$2.46M$76$91
FY2024
Jacqualyn AFouse Ph D
$0$0$2.46M$76$91
FY2023
Brian Goff
$3.42M$2.21M$2.44M$51$92
FY2023
Jacqualyn AFouse Ph D
$0$0$2.44M$51$92

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsOption awardsIncentive payOtherTotalvs. prior year
Brian Goff
Chief Executive Officer
$846.86K–$1.29M$2.63M$592.80K$11.79K$5.37M-21%
Cecilia Jones
Chief Financial Officer
$535.09K–$924.38K$802.01K$240.79K$15.96K$2.52M+4%
James Burns
Chief Legal Officer
$527.28K–$786.90K$802.01K$237.27K$15.96K$2.37M-3%
Sarah Gheuens, M.D., Ph.D.
Chief Medical Officer, Head of Research & Development
$601.06K–$397.44K$802.01K$270.48K$15.69K$2.09M-18%
Krishnan Viswanadhan, Pharm.D
Chief Corporate Development & Strategy Officer
$433.13K$250.00K$824.99K$1.05M$236.25K$12.13K$2.81M–

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Jul 24, 2013
Offer price
$18.00
Securities offered
5,888,888
Gross proceeds
$106.00M
Exchange
Nasdaq
First trading day
Jul 24, 2013
First-day close
$31.28+73.8%
Lock-up ends (est.)
Jan 20, 2014

“Our common stock has been approved for listing on The NASDAQ Global Select Market under the symbol “AGIO.” The initial public offering price is $18.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 539 full-time employees and 1 part-time employee.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?